About Entero Therapeutics Inc. - Common Stock (ENTO)
Entero Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders and related health conditions. The company is dedicated to advancing its proprietary drug delivery technologies and treatment strategies that target the gastrointestinal tract, aiming to improve the lives of patients with challenging medical issues. Through rigorous research and development, Entero is committed to addressing unmet medical needs in the field of digestive health and enhancing the effectiveness of existing therapies. Read More
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
BOCA RATON, FLORIDA / ACCESS Newswire / November 19, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company") today announced that its subsidiary Grid AI has executed a Letter of Intent (LOI) with a stealth-mode hyperscaler artificial intelligence (AI) data-center developer to deploy Grid AI's advanced power-cluster optimization and orchestration platform at the customer's first large-scale AI campus. The campus-expected to be among the more sophisticated AI-ready digital-infrastructure sites in development-will be located in the ERCOT market in Texas.
BOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics (NASDAQ:ENTO) has just made one of the boldest moves in its history, a reinvention that trades long biotech timelines for immediate impact. By acquiring GRID AI, Entero has vaulted straight into the nexus of two of the decade's biggest themes: the surge in AI-driven energy demand and the transformation of the grid to handle it. The acquisition also facilitated the company's return to full compliance with Nasdaq listing requirements, marking not just a strategic but also a structural milestone.
BOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics, Inc. ("Entero" or the "Company") (NASDAQ:ENTO) is pleased to announce that, as a result of the acquisition of 100% of Grid AI Corp. ("Grid AI"), it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule").
BOCA RATON, FL / ACCESS Newswire / October 16, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) ("ENTO" or the "Company") a company pioneering innovation at the intersection of biotechnology and AI-driven energy infrastructure launches Grid AI Corp., to redefine how artificial intelligence infrastructure connects to the power grid.
BOCA RATON, FL, NY / ACCESS Newswire / October 14, 2025 / Entero Therapeutics (NASDAQ:ENTO) has reinvented itself in a way few public companies dare. By acquiring GRID AI, it has stepped directly into one of the most urgent races of the decade: making sure energy can keep pace with the accelerating appetite of artificial intelligence. The Entero story is now less about enzymes and long clinical trials. It is now about electricity, orchestration, and scale.
BOCA RATON, FL / ACCESS Newswire / October 14, 2025 / Entero Therapeutics (NASDAQ:ENTO) didn't tiptoe into reinvention. It jumped. The company, once known for enzymes and patient trials, is now in the grid game, acquiring GRID AI in a deal that rewires its entire identity. That may sound dramatic, but reinvention usually is. Investors who only saw a challenged biotech woke up to find the ticker transformed into a player in one of the most valuable races of the decade: making sure the power keeps flowing in an AI-driven world.
Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutions
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
